P-6157
Blood | 2025
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis.
Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin A, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A
PubMed
PMID: 40623049
CIBMTR Study #: LY20-02